Aerobic glycolysis enables cancer cells to rapidly take up nutrients (e.g., nucleotides, amino acids, lipids) and incorporate them into the biomass needed to produce a new cell. In contrast to existing chemotherapy/radiotherapy strategies, inhibiting aerobic glycolysis to limit ATP yield is a highly efficient approach for suppressing tumor cell proliferation. However, most, if not all, current inhibitors of aerobic glycolysis cause significant adverse effects, due to their nonspecific delivery and distribution to non-diseased organs, low bioavailability and a narrow therapeutic window. New strategies to enhance the biosafety and efficacy of these inhibitors are needed for moving them into clinical application. To address this need, we developed a liposomal nanocarrier functionalized with a well-validated tumor targeting peptide to specifically deliver the aerobic glycolysis inhibitor 3-bromopyruvate (3-BP) into tumor tissue. The nanoparticles effectively targeted tumors after systemic administration into tumor-bearing mice, and suppressed tumor growth by locally releasing 3-BP to inhibit ATP production of the tumor cells. No overt side effects were observed in the major organs. This report demonstrates the potential utility of the nanoparticle-enabled delivery of an aerobic glycolysis inhibitor as an anticancer therapeutic agent.
growing evidence that inhibiting aerobic glycolysis can directly induce tumor cell apoptosis through reducing ATP levels. The pyruvate mimetic 3-bromopyruvate is considered to be an effective inhibitor of glycolysis 6, 7 , and has shown remarkable efficacy in inducing tumor cell apoptosis and preventing tumor growth in preclinical studies [8] [9] [10] [11] . 3-BP is taken up into tumor cells via monocarboxylate transporter 1 (MCT1) which is overexpressed in most tumor cells, especially in hypoxic tumor regions [12] [13] [14] . Despite 3-BP showing considerable therapeutic potential against tumors, significant side effects, mainly owing to nonspecific delivery, distribution to non-diseased organs, low bioavailability and narrow therapeutic window, limit its clinical application 15 .
For in vivo use, the ideal scenario would be targeted delivery of therapeutic 3-BP to cancer cells that have particularly high expression of MCT1, thereby limiting side effects that result from nonspecific delivery as well as reducing the therapeutic dosage.
Motivated by this rationale, we constructed biodegradable and biocompatible liposomal nanoparticles for the targeted delivery of 3-BP agent to tumors (Figure 1 ).
We chose US Food and Drug Administration (FDA)-approved liposome components
to construct the nanoparticles, thereby facilitating the translation of this nanovehicle into clinical practice [16] [17] [18] [19] . We encapsulated 3-BP into nanoparticles using a filming-rehydration method, and covalently coupled a tumor targeting pentapeptide (Cys-Arg-Glu-Lys-Ala; CREKA) to their surface. CREKA recognizes fibrin-fibronectin complexes (microthrombi) which are specific for the tumor vascular endothelium, enabling the peptide-linked nanoparticles to accumulate at the site of the tumor in a self-amplifying manner 20, 21 . The resulting nanoformulation (T-Lipo-3BP) effectively targeted to tumor vessels following systemic administration and released 3-BP to selectively kill tumor cells by blocking ATP production (Figure 1 ). This approach not only inhibited the growth of the tumor, but showed no or minimal side effects, unlike free 3-BP. Our strategy allows 3-BP to be delivered safely and more effectively than free drug, and paves the way for its potential clinical usage. 
Materials and Methods

Materials
Synthesis of DSPE-PEG-CREKA
DSPE-PEG-CREKA was prepared according to methods described in our previous work 22 . Briefly, 8.5 mg DSPE-PEG-MAL and 1.78 mg CREKA peptide were dissolved in 4 mL of 10% methanol and stirred for 24 h at room temperature under anaerobic conditions. The solution was then dialyzed (molecular weight cutoff of Mr 1000) against tri-distilled water for 24 h and lyophilized for 48h.
Preparation and characterization of nanoparticles
T-Lipo-3BP and T-Lipo were prepared by a modified filming-rehydration method 22 .
In T-Lipo-3BP were assessed by dynamic light scattering (DLS) using a ZetaSizer Nano series Nano-ZS (Malvern Instruments Ltd., Malvern, UK). The morphology of T-Lipo-3BP and T-Lipo was characterized using transmission electron microscopy (TEM) with a negative staining method as previously described 22 and using a EM-200CX electron microscope (JEOL Ltd., Tokyo, Japan).
In vitro drug release profile of T-Lipo-3BP
The in vitro drug release kinetic profile of T-Lipo-3BP was evaluated by dialysis.
Briefly, 2 mL of T-Lipo-3BP was added to a dialysis bag (molecular weight cutoff of Mr 1000) and placed into 40 mL of PBS at pH 7.4 or pH 6.8 in a 50 mL tube. The tube was shaken at 37ºC. At various times, 1 mL of the outside buffer was removed and replaced with 1 mL of fresh PBS. The amount of 3-BP contained in the PBS was assayed using high-performance liquid chromatography (HPLC). In brief, a C18-alkyl reverse phase bonded column was chosen as the stationary phase. The mobile phase contained a 90/10 mixture of 0.1% trifluoroacetic acid in water/0.1% trifluoroacetic acid in acetonitrile. An isocratic elution method with a flow rate of 1 mL per minute and a run time of 5 minutes was used. 3-BP levels were assessed by measuring the absorbance using an ultraviolet detector at 204 nm. A standard curve for 3-BP was generated using drug concentrations of 0.1875, 0.375, 0.75, 1.5 and 3 mg/mL.
Samples were analyzed in triplicate and solvent alone was used as the blank.
Cytotoxicity assays
The mouse pancreatic cancer cell line Pan-02 was kindly supplied by Professor H.
Lee from Moffitt Cancer Center and Research Institute, Tampa, USA, and maintained at 37ºC and 5% CO2 in RPMI1640 medium supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin and streptomycin. The human breast cancer cell line MDA-MB-231 was purchased from China Infrastructure of Cell Line Resources (Peking Union). Mouse primary testis stromal cells (MTS) were isolated from immature mice as previously described 23 and were maintained at 37ºC and 5% CO2
in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin.
Authentication of the MDA-MB-231 cell line was performed by short tandem repeat DNA profiling and compared with a reference database. All the cell lines used in this work were shown to be free of mycoplasma contamination. For the cytotoxicity assay, the cell lines were seeded into 96-well plates at 37ºC and sub-cultured for 24 h. The cell cultured medium was subsequently replaced by fresh medium containing different 3-BP concentrations at different conditions. After further incubation for 24 h, the cell viability was assessed using a CCK-8 Kit assay.
Measurement of ATP levels
Pan-02 pancreatic cancer cells (1 x 10 6 ) were seeded into 6-well plates and cultured at 37ºC in 5% CO2 for 24 h. The medium was then replaced by a fresh medium containing 20 or 40 µM 3-BP. After incubation at 37ºC for 6 or 12 h, the cultured cells were collected and ATP was measured using an Enhanced ATP Assay Kit（Beyotime:
S0027） according to the manufacturer's instructions. For assessing intratumoral ATP levels, tumor tissues were harvested from pancreatic cancer tumor-bearing C57BL mice and analyzed according to the Enhanced ATP Assay Kit protocol.
Animal experiments
To For in vivo imaging experiments, Pan-02 tumor-bearing nude mice were injected intravenously with T-Lipo-3BP-Cy7. After 2 and 24 h, the biodistribution of nanoparticles was evaluated using a Maestro TM in vivo optical imaging system.
To assess the potential side effects of T-Lipo-3BP, C57BL mice bearing Pan-02 tumors were randomly divided into 5 groups: saline, 3-BP, T-Lipo-3BP, T-Lipo and Lipo-3BP. Meanwhile, the normal mice were used for healthy control. The mice were treated on three occasions at two day intervals. Two days after the final treatment, the mice were euthanized. Serum was collected for biochemical analysis and the major organs were resected for histopathology.
All animal procedures were approved by the Committee on the Ethics of Animal Experiments of the Health Science Center of Peking University (Beijing, China).
Western blotting
After treatment with varying drug concentrations, cells were harvested and lysed in RIPA buffer. The expression of MCT1 was subsequently analyzed by western blotting.
Total protein (20 g) was separated on 10% polyacrylamide gels and proteins were transferred to a polyvinylidene fluoride (PVDF) membrane.
Statistical analysis
Statistical analysis was conducted using the student t-test for comparison of two groups and one-way ANOVA for multiple groups, followed by Newman-Keuls test. A P value of less than 0.05 was considered significant.
Results and Discussion
Preparation and characterization of T-Lipo-3BP nanoparticles
To construct liposomal nanoparticles that target the tumor vasculature, we first Furthermore, the characteristic peaks of DSPE, PEG and MAL were clearly detected by NMR spectroscopy in the DSPE-PEG-MAL sample (Figure S3A ), while the MAL peak disappeared following the CREKA conjugation ( Figure S3B) . The CREKA peptide coated liposome nanoparticles loaded with 3-bromopyruvate (3-BP) were subsequently prepared using a thin-film dispersion hydration method, as described by us previously [22] . To optimize the drug loading efficiency, three different mass ratios (Table S1) , and this ratio was chosen for subsequent studies. Transmission electron microscopy (TEM) showed that the empty (T-Lipo) and drug-loaded (T-Lipo-3BP) liposomal nanoparticles had a typical spherical structure (Figure 2A and 2C) . Dynamic light scattering (DLS) analysis revealed a rather uniform size distribution for both nanoparticles, with a slight increase in the average hydrodynamic diameter from 141.5 nm for T-Lipo to 160.5 nm for T-Lipo-3BP (Figures 2B and 2D ) and the PDI were 0.169 and 0.090 respectively.
We 
MCT1-dependent in vitro cytotoxicity of T-Lipo-3BP
Monocarboxylate transporter 1 (MCT1), which is particularly highly expressed under hypoxic conditions, such as those found in the tumor microenvironment, is reported to mediate the cellular uptake of 3-BP in tumor cells [12] [13] [14] . To investigate the role of MCT1 in the uptake of T-Lipo-3BP-derived 3-BP, we first examined MCT1 expression in pancreatic cancer cells (Pan-02) and found that it was indeed more highly expressed under hypoxic conditions than in normoxia ( Figure S4A ). Figure 3D ). This suggests that ATP production from aerobic glycolysis was effectively blocked by T-Lipo-3BP treatment, and that this was the likely mechanism of cell death.
Consistent with this result
In vivo tumor targeting of T-Lipo-3BP
The ability to target cytotoxic agents direct to tumors plays a decisive role in efficient cancer therapy. To investigate the tumor targeting capability of T-Lipo-3BP, we examined the biodistribution of Cy7-labeled nanoparticles after intravenous administration into Pan-02 tumor-bearing mice. Two hours after nanoparticle administration, in vivo imaging showed a weak fluorescence signal over much of the mouse body, but there was a very strong fluorescence signal at the site of the tumor ( Figure 4A) . After 24 h, a strong fluorescence signal remained within the tumor region, but much less fluorescence was detected in other regions, confirming highly effective tumor targeting in vivo.
In vivo anti-tumor activity of T-Lipo-3BP
A prerequisite for in vivo anti-tumor activity of T-Lipo-3BP is that the target tumor expresses MCT1. We thus performed ex vivo immunohistochemistry of Pan-02 tumor tissue from our murine model and showed that the core of the tumors (~150 mm 3 ) had higher MCT1 expression, the same area where significant hypoxia-inducible factor 1
(HIF-1) expression was observed ( Figure S5 ). This confirmed that the central region of the tumors was highly anaerobic and that the model was an effective target for 3-BP.
The Pan-02 pancreatic tumor-bearing mice were then injected intravenously with To examine the mechanism by which T-Lipo-3BP killed tumor cells, we evaluated apoptosis in the tumor tissue using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL). TUNEL-positive cells were much more abundant in T-Lipo-3BP-treated tumors than in the other groups ( Figure   S6 ). We also observed that T-Lipo-3BP significantly reduced intratumoral ATP production ( Figure 4D ), while free 3-BP treatment only decreased the ATP level slightly.
In vivo tolerability of T-Lipo-3BP
The in vivo safety of T-Lipo-3BP was evaluated using normal C57BL mice. After intravenous administration of T-Lipo-3BP on three occasions at two day intervals, no loss of body weight was detected, with a similar result to the saline control group (Figure S7) . We also performed histological examination of the major organs including the heart, liver, spleen, lung and kidney. Systemic administration of T-Lipo-3BP did not induce damage in any of the organs examined (Figure 5A ), while administration of free 3-BP resulted in some adverse pathology in the liver. This is notable because serious liver burden is the dose-limiting side effect of free 3-BP in the clinical setting. We further investigated whether T-Lipo-3BP treatment resulted in functional abnormalities in the major organs of mice by assessing serum concentrations of biochemical indicators of liver, heart and renal function. Following three doses of T-Lipo-3BP, no significant changes in any of the indicators were observed compared with saline group. In contrast, free 3-BP significantly increased total bilirubin (TBIL; a well-known marker of liver cell damage) in the serum (Figures 5B and S8 ).
Conclusions
In summary, we have developed a tumor vascular endothelium targeted liposome nanoparticle (T-Lipo-3BP) to specifically deliver the aerobic glycolysis inhibitor 3-BP to MCT1-overexpressing tumors in mice. We chose liposomes as the controlled release system because its safety in clinical use has been well established. T-Lipo-3BP
nanoparticles were able to efficiently and safely deliver 3-BP to the tumor following systemic administration and therefore represent a promising vehicle targeting the aerobic glycolysis pathway of tumor cells overexpressing MCT1. The lack of detectable severe side effects, especially the hepatotoxicity that is characteristic of 3-BP, marks a major improvement over the current free aerobic glycolysis inhibitors.
We believe that this technique not only provides an effective strategy for the clinical application of 3-BP, but also could be applied for the delivery of other aerobic glycolysis targeting drugs to expand the utility of this therapeutic technology.
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